The target prediction methods identified 40 potential targets for baricitinib and 58 for tofacitinib (online supplementary tables 1 and 2, respectively). From all predicted targets, five targets for baricitinib and five for tofacitinib were identified as being relevant for thrombosis (Table ). For viral infection/reactivation (Table ), four targets were identified for baricitinib and three for tofacitinib. Table . Suggested targets with impact on thrombosis stratified by JAK inhibitor. *Commercial assays were unavailable for TRPC6 or TRPC3, and therefore, these targets could not be validated. Instead, transient receptor potential cation channel subfamily M member 6 (TRPM6) was employed for the respective binding assays.